BACKGROUND: The purpose of the present study was to evaluate graft and patient survival and long-term outcomes of primary endoluminal stenting (PES) as an initial treatment for transplant renal artery stenosis (TRAS). METHODS: From December 1999 to March 2010, 744 consecutive patients undergoing renal transplantation were enrolled. Patients were divided into one of two groups: the study group, comprised of 18 patients who underwent PES for TRAS > 60%, and a control group, including the remaining 726 recipients who did not develop TRAS post-transplantation. Primary outcome measures were death-censored graft failure and all-cause mortality. The immediate and long-term effects of PES were evaluated by assessing blood pressure (BP) control and biochemical graft function. RESULTS: The technical success rate for PES was 100%, and minor complication occurred in only one case (5.6% of the study group). With a mean follow-up of 7.1 ± 3.7 and 6.9 ± 2.4 years in the study and control groups, respectively, 4 patients in the study group and 113 patients in the control group reached the primary outcome (log rank P = 0.418). The reduction in stenosis resulted in immediate improvement in BP control and graft function, which persisted throughout the 6 year follow-up period. Restenosis occurred in only one patient (5.6%), but restenosis was not the cause of graft failure. CONCLUSIONS: This study indicated that both the long-term graft and patient survival were as good in TRAS patients treated with PES as in patients without TRAS. The data also supported the use of PES as an initial treatment for TRAS.
BACKGROUND: The purpose of the present study was to evaluate graft and patient survival and long-term outcomes of primary endoluminal stenting (PES) as an initial treatment for transplant renal artery stenosis (TRAS). METHODS: From December 1999 to March 2010, 744 consecutive patients undergoing renal transplantation were enrolled. Patients were divided into one of two groups: the study group, comprised of 18 patients who underwent PES for TRAS > 60%, and a control group, including the remaining 726 recipients who did not develop TRAS post-transplantation. Primary outcome measures were death-censored graft failure and all-cause mortality. The immediate and long-term effects of PES were evaluated by assessing blood pressure (BP) control and biochemical graft function. RESULTS: The technical success rate for PES was 100%, and minor complication occurred in only one case (5.6% of the study group). With a mean follow-up of 7.1 ± 3.7 and 6.9 ± 2.4 years in the study and control groups, respectively, 4 patients in the study group and 113 patients in the control group reached the primary outcome (log rank P = 0.418). The reduction in stenosis resulted in immediate improvement in BP control and graft function, which persisted throughout the 6 year follow-up period. Restenosis occurred in only one patient (5.6%), but restenosis was not the cause of graft failure. CONCLUSIONS: This study indicated that both the long-term graft and patient survival were as good in TRAS patients treated with PES as in patients without TRAS. The data also supported the use of PES as an initial treatment for TRAS.
Authors: J Buturović-Ponikvar; A Zupunski; A Urbancicc; A Kandus; M Malovrh; A Gucek; A Bren; R Ponikvar Journal: Transplant Proc Date: 2001 Nov-Dec Impact factor: 1.066
Authors: V Audard; M Matignon; F Hemery; R Snanoudj; P Desgranges; M C Anglade; H Kobeiter; A Durrbach; B Charpentier; P Lang; P Grimbert Journal: Am J Transplant Date: 2006-01 Impact factor: 8.086
Authors: G Benoit; C Hiesse; P Icard; H Bensadoun; J Bellamy; B Charpentier; A Jardin; D Fries Journal: Transplant Proc Date: 1987-10 Impact factor: 1.066
Authors: N H Patel; R M Jindal; T Wilkin; S Rose; M S Johnson; H Shah; J Namyslowski; K P Moresco; S O Trerotola Journal: Radiology Date: 2001-06 Impact factor: 11.105
Authors: M Rengel; G Gomes-Da-Silva; L Incháustegui; J L Lampreave; R Robledo; A Echenagusia; J L Vallejo; F Valderrábano Journal: Kidney Int Suppl Date: 1998-12 Impact factor: 10.545
Authors: S M Greenstein; A Verstandig; G K McLean; D C Dafoe; D R Burke; S G Meranze; A Naji; R A Grossman; L J Perloff; C F Barker Journal: Transplantation Date: 1987-01 Impact factor: 4.939
Authors: Chelsea C Estrada; Muzammil Musani; Frank Darras; Heesuck Suh; Mersema T Abate; Anil Mani; Edward P Nord Journal: Transplant Direct Date: 2017-01-17